http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Clene's (CLNN) CNM-Au8 Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) levels in the HEALEY ALS Platform Trial
-
Clene’s CNM-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) levels in the HEALEY ALS Platform Trial
-
Clene to Participate in the Maxim Group Virtual Healthcare Conference
-
Clene Awarded Grant From National Multiple Sclerosis Society to Advance Development of CNM-Au8® in Non-Active Progressive Multiple Sclerosis
-
Clene Reports First Quarter 2023 Financial Results and Recent Operating Highlights
-
ALS and MS Clinical Data from Clene’s CNM-Au8® Featured in Multiple Presentations at the 2023 American Academy of Neurology Annual Meeting
-
Clene Announces the Plenary Presentations of MS and ALS Data Supporting the Efficacy and Safety of CNM-Au8® at the 2023 American Academy of Neurology Annual Meeting
-
Clene Appoints Neurology Expert to Executive Team
-
Clene Reports Full Year 2022 Financial Results and Recent Operating Highlights
-
Clene (CLNN) Announces CNM-Au8 Associated With Delayed Time to Key Clinical Progression Events at Six Months Supporting a Survival Benefit in the Healey ALS Platform Trial
-
CNM-Au8® Associated With Delayed Time to Key Clinical Progression Events at Six Months Supporting a Survival Benefit in the Healey ALS Platform Trial
-
Clene (CLNN) to Announce New CNM-Au8 Data From the Healey ALS Platform Trial
-
Clene to Announce New CNM-Au8® Data From the Healey ALS Platform Trial
-
Clene Nanomedicine to Participate in Roth’s 35th Annual Healthcare Conference and Renmark Virtual Non-Deal Roadshow Series
-
Clene (CLNN) Announces New Data Show CNM-Au8 Preserved ALS Patient Function and Slowed Disease Progression in the Open-Label Extension of the Phase 2 RESCUE-ALS Trial
-
New Data Show CNM-Au8® Preserved ALS Patient Function and Slowed Disease Progression in the Open-Label Extension of the Phase 2 RESCUE-ALS Trial
-
Clene (CLNN) Announces Updated VISIONARY-MS Phase 2 Trial Data
-
Clene Announces Updated VISIONARY-MS Phase 2 Trial Data Presented at 2023 ACTRIMS Forum Show CNM-Au8® Demonstrated Significant Improvements in Clinical Outcomes, Brain Structure, and Visual System
-
Clene (CLNN) Reports New Data from the VISIONARY-MS Phase 2 Study
-
Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity
-
Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity
-
Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23
-
Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23
-
Clene (CLNN) Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg
-
Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg
-
Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg
-
Clene Announces Closing of $5 Million Debt Facility from the State of Maryland
-
Clene Announces Closing of $5 Million Debt Facility from the State of Maryland
-
VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying T
-
VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying T
-
Clene Reports Third Quarter 2022 Financial Results and Recent Operating Highlights
-
Clene Reports Third Quarter 2022 Financial Results and Recent Operating Highlights
-
Clene (CLNN) Announces $10.8 Million Registered Direct Offering and $5 Million Debt Facility from the State of Maryland
-
Clene Announces $10.8 Million Registered Direct Offering and $5 Million Debt Facility from the State of Maryland
-
Clene Announces $10.8 Million Registered Direct Offering and $5 Million Debt Facility from the State of Maryland
-
Clene (CLNN) Reports Mixed Results for CNM-Au8 in Healey ALS Platform Trial
-
Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial
-
Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial
-
Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3
-
Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3
-
Clene (CLNN) Presents Updated Long-Term Survival Data from RESCUE-ALS
-
Clene Nanomedicine Presents Updated Long-Term Survival Data from RESCUE-ALS Participants at 2022 AANEM Scientific Conference
-
Clene Nanomedicine Presents Updated Long-Term Survival Data from RESCUE-ALS Participants at 2022 AANEM Scientific Conference
-
Clene to Present at Upcoming September Investor Conferences
-
Clene to Present at Upcoming September Investor Conferences
-
Clene (CLNN) Reports Positive Topline Phase 2 Results for CNM-Au8
-
Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis
-
Clene Reports Second Quarter 2022 Financial Results and Recent Operating Highlights
-
Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis
-
Clene Reports Second Quarter 2022 Financial Results and Recent Operating Highlights
